Equasens (EQS) AI Stock Analysis

• Market Cap: €610.58M
• Dividend Yield: 3.24%
• Average Volume (3M): 10.91K
• Price to Earnings (P/E): 16.8
• Beta (1Y): 0.59
• Revenue Growth: 4.45%
• EPS Growth: -14.08%
• Country: FR
• Employees: 1,271
• Sector: Services
• Sector Strength: N/A
• Industry: Medical - Healthcare Information Services
• EPS (TTM): 1.15
• Shares Outstanding: 15,174,125
• 10 Day Avg. Volume: 9,833
• 30 Day Avg. Volume: 10,915
• PEG Ratio: -0.81
• Price to Book (P/B): 2.90
• Price to Sales (P/S): 3.10
• P/FCF Ratio: 18.70
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 69 Neutral
• Price Target: €44.00 ▲(13.99% Upside)

Equasens demonstrates strong financial performance with robust cash flow and profitability margins, which is the most significant factor in its overall score. The valuation is reasonable, supported by a solid dividend yield. However, technical analysis indicates a bearish trend, which slightly offsets the positive financial and valuation aspects.

Positive Factors

Business Model Strength

Equasens' diverse revenue streams from subscriptions and device sales provide a stable and recurring income base, enhancing financial resilience.

Cash Generation Ability

Strong cash flow supports ongoing investments and provides financial flexibility, crucial for sustaining growth and operational health.

Market Position

As a leader in healthcare technology, Equasens benefits from a strong market position, driving innovation and competitive advantage.

Negative Factors

Revenue Growth Challenges

The recent dip in revenue growth may indicate challenges in market expansion or product adoption, impacting long-term growth prospects.

Rising Liabilities

Increasing liabilities could strain financial resources, requiring careful management to maintain financial stability and operational flexibility.

Earnings Decline

A decline in earnings per share growth can signal potential profitability issues, affecting investor confidence and future investment capacity.

Equasens Business Overview & Revenue Model

Company Description

Equasens Société anonyme provides various IT solutions for the healthcare sector in Europe. It offers LGPI global services and OffiCentral solutions for managing pharmacies and their networks; OffiMSS, OffiSecure, OffiProtect, OffiPass, OffiSeen, OffiCash, Offizzy, and OffiLocker solutions for pharmacists' business processes; and solutions for energizing the customer relationship with pharmacists comprising OffiTag, OffiTouch, OffiMédia, OffiConnect, automation systems, and customer loyalty programs. The company also provides My Pilot, an analytics and management tool; OffiLearning, an e-learning tool; and solutions for patient support and advice, such as compliance monitoring software, Multimeds, Automeds, and OffiTéléconsult, as well as pharmaceutical record and shared medical record services. In addition, it offers a ULTIMATE, a system combining optimized pharmacy management and improved patient support; FARMACLICK, a protocol for communications between pharmacies and wholesalers-distributors; DIFARM, a solution for wholesalers-distributors; PHARE, a retail management tool; SOPHIA, a pharmacy management application; OffiMédia POS display; eNephro to enhance the care of chronic renal failure patients; and TPE Pilot, a web-based application that simplifies the management and sharing of patient education programs. Further, the company provides NOVIACARE; CARELIB Domicile; CARELIB EHPAD; KAPELSE solutions; TITAN solutions; ANTHADINE software and MOBISOINS mobile tool; MICROSOINS, an in-home nursing care solution; and LOGICLIC. Additionally, it offers AXIGATE solutions to manage the entire patient care pathway; CHORUS platform; medical telesecretarial services for healthcare professionals; and equipment lease financing solutions. The company was incorporated in 1996 and is based in Villers-les-Nancy, France. Equasens Société anonyme is a subsidiary of Marque Verte Sante.

How the Company Makes Money

Equasens generates revenue through multiple streams, primarily by offering subscription-based models for its telemedicine and digital health platforms. Revenue is also derived from the sale of connected medical devices that enable remote patient monitoring and data collection. Additionally, the company partners with healthcare institutions and insurance providers to implement its technology solutions, often leading to contractual agreements that secure ongoing service fees. Significant partnerships with technology firms and healthcare organizations enhance its market reach and contribute to its revenue through collaborative projects and shared technology initiatives.

Equasens Financial Statement Overview

Summary

Equasens presents a strong financial profile with consistent revenue growth and solid profitability margins. The balance sheet reflects stability with a healthy equity position, while cash flow statements confirm strong cash generation. Despite slight challenges in revenue growth and rising liabilities, the company's financial health remains robust, supported by efficient operations and financial management.

Income Statement

Equasens has demonstrated consistent revenue growth over the years, with a compound annual growth rate in revenue evident from 2019 to 2023. The gross profit margin and EBIT margin have been healthy, indicating effective cost management and operational efficiency. However, a slight decrease in revenue from 2023 to 2024 suggests a potential challenge in sustaining growth, although margins remain strong.

Balance Sheet

Equasens exhibits financial stability with a strong equity ratio, indicating a solid financial foundation. The debt-to-equity ratio remains manageable, showcasing prudent leverage management. The return on equity is commendable, although a slight increase in liabilities in recent years suggests a need to monitor debt levels closely.

Cash Flow

The company maintains robust cash flow generation capabilities, with positive free cash flow and a consistent operating cash flow to net income ratio. Free cash flow growth has been notable, supporting ongoing investments and financial flexibility. The cash flow management reflects strong operational health.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	224.81M	216.80M	219.79M	214.07M	193.07M	171.75M
Gross Profit	40.63M	47.13M	69.88M	145.52M	133.82M	119.31M
EBITDA	53.65M	62.99M	71.30M	67.36M	63.77M	55.82M
Net Income	37.15M	36.20M	47.05M	46.38M	39.12M	30.71M
Balance Sheet
Total Assets	410.92M	398.01M	394.05M	350.81M	329.95M	295.78M
Cash, Cash Equivalents and Short-Term Investments	81.73M	40.16M	54.69M	68.01M	64.79M	63.28M
Total Debt	49.13M	48.45M	69.27M	66.52M	84.06M	71.81M
Total Liabilities	171.66M	157.32M	166.42M	154.01M	164.72M	146.82M
Stockholders Equity	229.97M	231.51M	219.28M	189.78M	159.00M	143.26M
Cash Flow
Free Cash Flow	50.88M	35.91M	43.17M	46.75M	37.09M	27.53M
Operating Cash Flow	53.39M	47.55M	61.59M	56.98M	47.52M	47.21M
Investing Cash Flow	-19.88M	-13.90M	-50.53M	-18.34M	-36.19M	-39.14M
Financing Cash Flow	-40.92M	-36.20M	-16.09M	-39.88M	-9.80M	4.16M

Equasens Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 38.60
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:EQS, the sentiment is Negative. The current price of 38.6 is below the 20-day moving average (MA) of 40.02, below the 50-day MA of 43.12, and below the 200-day MA of 42.44, indicating a bearish trend. The MACD of -1.05 indicates Negative momentum. The RSI at 36.37 is Neutral, neither overbought nor oversold. The STOCH value of 30.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:EQS.

Equasens Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EQS	―	€610.58M	16.83	16.40%	3.24%	4.45%	-14.08%
BLC	―	€176.97M	365.17	3.97%	―	-7.28%	―
LNA	―	€236.54M	11.20	6.64%	2.85%	13.31%	-13.07%
ALCGM	―	€161.83M	―	-5.21%	―	3.79%	-797.10%
Sector *	―	$13.29B	17.42	10.03%	0.93%	7.13%	-12.93%
ALERS	―	€246.13M	104.86	1.32%	―	12.47%	-65.87%
GDS	―	€997.67M	―	-4.36%	―	4.70%	-0.33%